“ApoB predicts heart risk better than LDL cholesterol.”
Moderate confidence because apoB measures the number of circulating atherogenic particles, and a large prospective discordance analysis found that apoB retained risk information when LDL-C did not. Most people have broadly concordant values, the key comparative evidence is observational, and major guidelines still use LDL-C as the primary treatment marker.
ApoB can predict atherosclerotic cardiovascular risk more accurately than LDL cholesterol, especially when the two measures are discordant. LDL-C remains a useful, widely used marker.
Each atherogenic particle carries one apoB molecule, while LDL-C measures the cholesterol mass inside LDL particles. The same LDL-C can therefore reflect different particle numbers. ApoB may add the most context when triglycerides are high, diabetes or metabolic syndrome is present, or results otherwise do not fit the clinical picture.
Safety note: ApoB is one risk marker, not a diagnosis or a reason to change treatment by itself. Decisions should include blood pressure, smoking, diabetes, kidney disease, family history and overall cardiovascular risk.
Talk to a healthcare professional if: Ask whether apoB would change management if your triglycerides are high, you have diabetes or metabolic syndrome, premature cardiovascular disease runs in your family, or LDL-C seems inconsistent with your overall risk.
ApoB can refine a standard lipid assessment because it counts atherogenic particles. It does not make LDL-C useless or mean everyone needs an extra test.
Review your standard lipid panel and overall risk first. Ask whether an apoB result would change a treatment decision in your situation.